Most important take away

Scientists have already discovered medicines to prevent most of the diseases that kill us — the gap is not invention, it’s impact (getting people on them early). GLP-1s are the first commercial proof of a proactive “health stack” model that could deliver a once-in-a-lifetime, trillion-dollar reduction in healthcare spending. The biggest asymmetric opportunity is PCSK9 inhibitors, which Karnal argues are the closest thing to a “free lunch” drug in medicine today.

Chapter Summaries

• State of the Union (2025–2026): Most exciting year in Karnal’s 20-year career. GLP-1 adoption exceeded expectations; oral Wegovy at ~$150/month is driving a 4x faster launch curve than injectables — 300K new scripts/week.
• The Health Stack: Five defensive layers, each with approved medicines already available: lipid optimization (statins, PCSK9 inhibitors), cardio-metabolic health (GLP-1s), neurocognitive health (anti-amyloid drugs), inflammatory health, and blood pressure.
• GLP-1 Deep Dive: Mechanism explained — a 2-minute natural hormone now engineered to last a week. Wall Street over-indexes on maximal weight loss; patients actually want tolerable, low-dose, stay-on-it versions. Three barriers to impact: complexity, cost, compliance. Direct-to-consumer (Lilly Direct, Hims) + price elasticity is the real unlock.
• PCSK9 Inhibitors: Discovered via human genetics (a population with the mutation has 88% lower cardiovascular disease risk). Drugs cut LDL by 50% and cardiac events by 20–25%. Near-zero side effects. RNAi versions reduce dosing to 2x/year. Should eventually be bigger than GLP-1s.
• Alzheimer’s / Neurodegenerative: Biogen and Lilly anti-amyloid drugs slow decline ~30% in late-stage patients; the bet is that early intervention could prevent progression entirely.
• Cancer: Key is early detection. Exact Sciences (stool-based) and Guardant (blood-based) lead colorectal screening. Multi-cancer early detection blood tests are coming within 3–5 years. CAR-T and next-gen in-vivo versions (e.g., Capstan) show 100% tumor reduction in 70%+ of patients.
• Imaging (Prenuvo, Neko): Useful longitudinally but false-positive rates compound across dimensions; Karnal personally doesn’t use them yet.
• Drug Discovery + AI: AI is inevitable in pharma. Companies like Lila Sciences and Nabla can go from target to molecule in ~1 month vs. years. The real moat is generating novel proprietary data (robotic labs) since public literature is noisy and often not replicable. Expects fully automated discovery within 5–10 years.
• Citizen Pharmacology / FDA: Peptide community and Reddit-driven self-experimentation reflect a generational shift toward owning one’s health. FDA under Marty Makary moving to cut redundant trials and use AI to speed reviews.
• Karnal’s Personal Story: MIT → Merrill Lynch derivatives (biotech sub-desk by chance) → Deerfield at 24 for 15 years. Left Deerfield after realizing people weren’t actually taking the medicines he financed. Co-founded Braidwell with Brian Kreider (ex-Bridgewater COO) to build an “operating system for human health” focused on invention AND impact.

Summary

Actionable Health Insights

• Get a baseline blood panel focused on LDL cholesterol, glycemic markers, inflammation, and blood pressure. The “silent killer” framing: you don’t feel high cholesterol until it causes a heart attack.
• Oral Wegovy (~$150/month) is a real inflection — pricing elasticity is proven. If GLP-1s make sense for you, cost is no longer the barrier it was.
• PCSK9 inhibitors are the most asymmetric “free lunch” Karnal sees. The earlier you intervene, the better. Worth asking your doctor about, especially with family history of cardiovascular disease.
• Colonoscopies matter — colon cancer is slow-growing and highly preventable with regular screening. Guardant’s blood test lowers the friction barrier for those who won’t do stool-based tests or colonoscopies.
• Compliance is everything. Dosing frequency matters more than people realize — monthly or quarterly dosing medicines (Pfizer, Amgen GLP-1 pipeline) will dramatically improve real-world outcomes.
• Whole-body imaging (Prenuvo): Karnal is cautious — false positives compound and can be disruptive without proper diagnostic context.

Companies Mentioned (Investment / Watch List)

• Eli Lilly — Mounjaro/Zepbound (tirzepatide); anti-amyloid Alzheimer’s drug readout expected late 2026; Lilly Direct DTC channel.
• Novo Nordisk — Ozempic/Wegovy (semaglutide); oral Wegovy driving record-breaking launch curve.
• Biogen — Anti-amyloid Alzheimer’s.
• Exact Sciences — Stool-based colorectal cancer screening (Cologuard).
• Guardant Health — Blood-based colorectal cancer screening; positioned for multi-cancer early detection.
• Capstan Therapeutics — Next-gen in-vivo CAR-T (IV-injectable, no cell extraction needed).
• Pfizer — Acquired a once-monthly GLP-1 candidate.
• Amgen — Developing once-monthly / once-quarterly GLP-1.
• Hims & Hers — Captured 15–20% of GLP-1 market via compounded, price-elastic DTC model.
• Lila Sciences, Nabla — AI drug discovery; target-to-molecule in ~1 month.
• Prenuvo, Neko Health — Whole-body imaging (Karnal cautious on signal-to-noise).
• Braidwell — Karnal’s current firm. Thesis: be the capital engine behind medicine’s moment from invention to impact.

Career Advice (Explicit and Implied)

• Serendipity beats planning. Karnal didn’t pick biotech — he was assigned to the biotech sub-desk at Merrill’s derivatives group and fell in love.
• Apprenticeship compounds. He was 24 joining Deerfield with the next-youngest person at 40. He asked “a thousand questions a day” and got an unmatched education.
• Find the one person who cares. His pitch deck on life-sciences portfolio construction got crickets from most firms — one response (Deerfield) launched a 15-year career.
• Lessons from his father: Relentless entrepreneurial energy, but the regret of never sticking with anything long enough. Commit, don’t quit (mother’s mantra).
• Know when to pivot. After a decade, Karnal realized his capital was optimizing returns but not public health (patients weren’t actually taking the medicines). That insight spawned Braidwell.
• Build a “morning meeting” room intentionally. Braidwell’s 9:15 AM meeting assembles scientists, biostatisticians, commercial experts, AI experts, traders, and structured finance people — each contributing a specific superpower to three questions: will it work, is the market real, can we finance it attractively?

The Big Picture

The “trillion-dollar revolution” is not a new class of drugs — it’s closing the gap between invention and impact. The commercialization wins of 2025 (DTC channels, price elasticity, oral formulations) prove consumers will take their health into their own hands if the system makes it easy and affordable. The next unlock is pairing this consumer-driven adoption with AI-accelerated discovery (1-month molecule design vs. years) and early-detection diagnostics. The investor’s edge now lies in backing companies that reduce complexity, cost, and compliance friction — not just those inventing new molecules.